No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
SIBN Si-Bone
- 16.420
- -0.190-1.14%
Trading Jul 22 13:26 ET
676.58MMarket Cap-15203P/E (TTM)
16.560High16.185Low130.72KVolume16.560Open16.610Pre Close2.14MTurnover0.35%Turnover RatioLossP/E (Static)41.20MShares26.03052wk High4.09P/B606.87MFloat Cap11.76052wk Low--Dividend TTM36.96MShs Float37.210Historical High--Div YieldTTM2.26%Amplitude7.200Historical Low16.339Avg Price1Lot Size
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Morgan Stanley Maintains Si-Bone(SIBN.US) With Buy Rating, Maintains Target Price $21
Morgan Stanley analyst Drew Ranieri maintains $Si-Bone(SIBN.US)$ with a buy rating, and maintains the target price at $21.According to TipRanks data, the analyst has a success rate of 39.4% and a
SI-BONE To Report Second Quarter 2024 Financial Results on August 5, 2024
SANTA CLARA, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today
Express News | SI-BONE Inc. : Morgan Stanley Cuts Target Price to $21.00 From $25.00
Morgan Stanley Maintains Si-Bone(SIBN.US) With Buy Rating, Cuts Target Price to $21
Morgan Stanley analyst Drew Ranieri maintains $Si-Bone(SIBN.US)$ with a buy rating, and adjusts the target price from $25 to $21.According to TipRanks data, the analyst has a success rate of 39.4%
Morgan Stanley Lowers Price Target on SI-Bone to $21 From $25, Keeps Overweight Rating
SI-Bone (SIBN) has an average investment rating of buy among analysts polled by Capital IQ, with price targets ranging from $20 to $32.
Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know
Comments
The recent insider sale of SI-BONE shares and the absence of insider purchases over the past year might worry investors. The low level of insider ownership and recent selling activity could indicate a misalignment between insiders and other shareholders.
Have Insiders Sold SI-BONE Shares Recently?SI-BONE's high P/S ratio is justified by its superior revenue growth and future prospects. Shareholders are confident in the company's future revenues, keeping the share price buoyant.
Multiple insider stock sales over the past year, including a notable sale at the current price, suggests reduced confidence in the firm's equity. The lack of insider purchases enhances these doubts about prospective share performance. Even with insider ownership, the ongoing sell-off hints at a careful approach to buying the company's stock.
The company's future could potentially bright despite underperformance, due to revenue growth. However, past unprofitability may have affected investors' sentiment. Note the 3 warning signs for SI-BONE as possible risks.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg